NeoCura Biotech Named Among 'Top 10 AI/Computational Drug Discovery Innovators in China 2021'

From October 11 to 13, the “Tianfu Health Talk - CHS 2021 6th China Healthcare Industry Upgrade Summit” was held in Chengdu. The summit explored topics including market environments, investment hotspots, and industrial transformations across seven key sub-sectors, such as digital healthcare, AI and computation-driven new drug R&D, and smart elderly care, and released the “2021 China Healthcare Industry Integrated Innovation List.”NeoCura was listed among the "2021 Top 10 Innovative AI/Computational Drug Development Enterprises in China" by virtue of its outstanding capabilities in AI-driven innovative RNA drug R&D.

As new technologies continuously break through specialized medical sub-sectors, boundaries between various fields are dissolving into a trend of convergence, opening up an entirely new perspective. Amid the interactive and integrated development of the healthcare industry, numerous innovative forces have emerged. The "2021 Top 10 Innovative AI/Computational Drug Discovery Enterprises in China" ranking aims to identify the most innovative and dynamic AI-driven pharmaceutical companies in China, showcase the value of AI-powered new drug R&D, and bridge the innovation ecosystem network to propel the innovative development of emerging industries.
 
For this selection cycle, the judging committee, adhering to the principles of fairness and impartiality, took into consideration both hard metrics—such as the company's establishment date, financing rounds, and operational status—and soft factors, including the market prospects of the respective sectors, project innovativeness, product differentiation, and corporate brand awareness. Following multiple rounds of evaluation, 10 outstanding AI-driven pharmaceutical innovation enterprises were ultimately selected.NeoCura's honorable listing as a rising star in AI-driven RNA therapeutics R&D also reflects the industry's recognition of its comprehensive capabilities.

Currently, the exploration and application of AI in drug discovery and development are accelerating. The increasing maturity of artificial intelligence has provided a powerful impetus for the advancement of innovative drugs. At the “AI and Computation-Driven New Drug R&D Industry Forum,” attendees engaged in in-depth discussions on “How AI and Computation Drive New Drug Development.”
 
Dr. Wang Yi, Founder and CEO of NeoCura, stated：“NeoCura, as a high-tech enterprise empowering the R&D of innovative RNA therapeutics with AI, primarily leverages AI for in-depth drug target discovery and fully automated drug design. The company has already conducted extensive research in the oncology field and is currently accelerating the continuous iterative innovation of its technology platform, the accumulation of standardized large-scale data, and the productization of its R&D achievements. In the short term,AI can not only effectively reduce R&D costs, but also significantly enhance the efficiency and accuracy of target screening. In the future, we will continue to unlock the potential of AI to safeguard human health.”
 
NeoCura is committed to building an internationally leading RNA innovative drug platform. It has independently developed an AI bioinformatics target discovery platform, an RNA therapeutics platform, a fully automated drug design platform, a multi-omics big data acquisition and analysis platform, and a drug screening and validation platform. The synergistic integration of these five scientific platforms drives forward RNA drug research.Its independently developed and proprietary NeoCura™ AI ALPINE tumor neoantigen prediction system ranks first globally in prediction accuracy.

The road ahead is long and arduous, yet NeoCura will continue to wield innovation as its spear and technology as its shield, accelerating the advancement of its R&D pipeline to deliver superior therapeutic solutions for patients through intelligent oncology.

Managing Editor: Bai Ji